Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 6/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902025 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CSF1RKIT | |
| SCHEMBL5472052 | 0.84 | HDAC1 (0.38) | SLC6A2SLC6A4PSMB5HDAC1HDAC2 | |
| SCHEMBL5474077 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CSF1RKIT | |
| SCHEMBL16320167 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16357123 | 0.79 | HDAC1 (0.38) | PSMB5HDAC1HDAC2HDAC3CSF1R | |
| SCHEMBL5475213 | 0.78 | HDAC1 (0.40) | PSMB5HDAC1HDAC2HDAC3CSF1R | |
| Hydrochloric Acid SCHEMBL5654851 | 0.78 | CSF1R (0.49) | PSMB5HDAC1HDAC2HDAC3CSF1R | |
| SCHEMBL5651332 | 0.78 | CSF1R (0.49) | PSMB5HDAC1HDAC2HDAC3CSF1R | |
| SCHEMBL14385170 | 0.76 | CSF1R (0.49) | CSF1RKIT | |
| SCHEMBL4187789 | 0.76 | CSF1R (0.52) | PSMB5HDAC1HDAC2HDAC3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | SLC6A2 3973/4885SLC6A4 3756/4885SLC6A3 3754/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | SLC6A2 3973/4885SLC6A4 3756/4885SLC6A3 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.